## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.15 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (54% of avg), momentum weakening (-1.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($192.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251231T084805 | Neutral | Relevance: 100%
- Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (NYSE:CRL) by 4.9%, selling 113,185 shares. The firm now holds 2,177,941 shares, valued at approximately $371.3 million, making CRL its 21st biggest holding. Other institutional investors have also adjusted their positions, with several increasing their holdings in the medical research company.

**2. 3 Overrated Stocks We Steer Clear Of**
- Source: Finviz | 20260101T070931 | Bearish | Relevance: 89%
- This article identifies three stocks—nLIGHT (LASR), Charles River Laboratories (CRL), and Royalty Pharma (RPRX)—that are considered overrated despite approaching their 52-week highs. The author advises caution due to concerns like slow revenue growth, cash burn, diminishing returns, and high valuations, suggesting investors look for higher-quality alternatives.

**3. Evotec SE: How a Quiet Drug Discovery Powerhouse Became a Strategic Platform Play**
- Source: AD HOC NEWS | 20260103T010946 | Neutral | Relevance: 65%
- Evotec SE is transforming from a service-oriented company into a data-driven drug discovery platform, focusing on powering big pharma pipelines, co-owned assets, and precision medicine. The company distinguishes itself through human-centric R&D, a platform approach rather than project-based services, and a co-ownership economic model. Its offerings include integrated R&D services, proprietary data-rich platforms, and the biologics industrialization platform Just – Evotec Biologics, positioning it as a strategic partner in the biopharmaceutical industry.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 18.5x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $205.00 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 18.5 |
| Current P/E | 19.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.3% to 3.8% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 54% of 20MA suggests lack of conviction. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.76% (CS: 85) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.101x | Above |
| vs SMA200 | 1.277x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $202.42
- **Stop Loss:** $192.76 (4.8% risk)
- **Target:** $221.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $30,160.58
- **Portfolio %:** 30.16%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*